Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06826339

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform (Matriarch) Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
340 (estimated)
Sponsor
Tiger Biosciences, LLC. · Industry
Sex
All
Age
21 Years
Healthy volunteers
Not accepted

Summary

Title A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform (Matriarch) Trial Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care versus Standard of Care alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

Detailed description

To determine the between-arm difference in the proportion of subjects achieving complete closure of nonhealing diabetic foot ulcers and venous leg ulcers with multiple CAMPs plus SOC versus SOC alone over 12 weeks using a modified dual platform (Matriarch) trial design.

Conditions

Interventions

TypeNameDescription
OTHERACApatch™Participants will receive weekly applications of ACApatch™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
OTHERcaregraFT™Participants will receive weekly applications of caregraFT™ and Standard of Care until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
OTHERStandard of CareBeginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.

Timeline

Start date
2024-12-06
Primary completion
2027-12-01
Completion
2027-12-01
First posted
2025-02-13
Last updated
2025-02-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06826339. Inclusion in this directory is not an endorsement.